Investigating Catalase and Carbonic Anhydrase Enzyme Activities and Levels of Certain Trace Elements and Heavy Metals in Patients with Primary and Metastatic Hepatic Carcinoma


Hepatocellular carcinoma (HCC) is among most common terminal cancer types in the world. Primary etiological factors include cirrhosis, hepatitis, aflatoxin and alcohol. The current study was conducted to determine cytosolic erythrocyte carbonic anhydrase and catalase enzyme activities and levels of some trace elements. For this purpose, 40 patients with primary and metastatic hepatic cancer and 29 healthy volunteers enrolled to the study. Catalase and carbonic anhydrase enzyme activities and serum trace element levels were measured in patient and control groups. In the current study, serum copper, magnesium, manganese and zinc levels were lower in the primary and metastatic hepatic cancer group in comparison with the control group (P < 0.05). In contrast, serum iron, cobalt, cadmium and lead levels were higher in the patient relative to the control group (P < 0.05). In comparison with the control group, the catalase level was lower in primary and metastatic cancer group, while the carbonic anhydrase level was higher in the cancer group (P < 0.05). Changes in levels of trace elements and anti-oxidant enzymes may be the factors which influence the development and progression of liver cancer. The carbonic anhydrase enzyme can be a useful indicator in the diagnosis of cancer. However, this issue warrants further investigation.

Share and Cite:

A. Arslan, H. Demir and H. Arslan, "Investigating Catalase and Carbonic Anhydrase Enzyme Activities and Levels of Certain Trace Elements and Heavy Metals in Patients with Primary and Metastatic Hepatic Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 8, 2013, pp. 1373-1381. doi: 10.4236/jct.2013.48163.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. Mazzanti, L. Gramantieri and L. Bolondi, “Hepatocellular Carcinoma: Epidemiology and Clinical Aspects,” Molecular Aspects of Medicine, Vol. 29, No. 1-2, 2008, pp. 130-143. 10.1016/j.mam.2007.09.008
[2] C. Müller, “Hepatocellular Carcinoma-Rising Incidence, Changing Therapeutic Strategies,” Wiener Medizinische Wochenschrift, Vol. 156, No. 13-14, 2008, pp. 404-409. 10.1007/s10354-006-0316-3
[3] H. Varolgünes, A. Inan, E. Kaptanoglu and S. Demirci, “Methods of Treatment Primary and Metastatic Liver Tumors,” Journal of Ankara University Faculty of Medicine, Vol. 50, No. 4, 1997, pp. 209-230.
[4] E. G?ksoy and M. Kapan, “Primary Malignant Tumors of the Liver. Hepato-Biliary System and Pancreas Diseases,” Symposium Series, Vol. 28, 2002, pp. 159-182.
[5] B. Haliwell and J. Gutteridge, “Oxygen Is Poisonous: An Introduction to Oxygen Toxicity and Free Radicals,” In: B. Halliwell and J. Gutteridge, Eds., Free Radicals in Biology and Medicine, Clarendon Press, Oxford, 1989, pp. 1-21.
[6] C. E. Cross, B. Halliwell and E. T. Borish, “Oxygen Radicals and Human Disease,” Annals of Internal Medicine, Vol. 107, No. 4, 1987, pp. 526-545.
[7] K. Asayama, T. Nakane and H. Uchida, “Serum Antioxidant Status in Streptazosin-Induced Diabetic Rat,” Hormone and Metabolic Research, Vol. 26, 1994, pp. 617-620.
[8] C. Lindholm, A. Acheva and S. Salomaa, “Clastogenic Plasma Factors: A Short Overview,” Radiation and Environmental Biophysics, Vol. 49, No. 2, 2010, pp. 133-138.
[9] C. T. Supuran and A. Scozzafava, “Carbonic Anhydrase Inhibitors,” Current Medicinal Chemistry—Immunology, Endocrine & Metabolic Agents, Vol. 1, No. 1, 2001, pp. 61-97. 1568013013359131
[10] D. Hewett-Emmett and R. E. Tashian, “Functional Diversity, Conservation, and Convergence in the Evolution of the [Alpha]-, [Beta]-, and [Gamma]-Carbonic Anhydrase Gene Families,” Molecular Phylogenetics and Evolution, Vol. 5, No. 1, 1996, pp. 50-77. mpev.1996.0006
[11] S. Parkkila, A. K. Parkkila, T. Juvonen, V. P. Lehto and H. Rajaniemi, “Immunohistochemical Demonstration of the Carbonic Anhydrase Isoenzymes I and II in Pancreatic Tumors,” The Histochemical Journal, Vol. 27, No. 2, 1995, pp. 133-138.
[12] W. R. Chegwidden, S. J. Dodgson and I. M. Spencer, “The Roles of Carbonic Anhydrase in Metabolism, Cell Growth and Cancer in Animals,” In: W. R. Chegwidden, N. D. Carter and Y. H. Edwards, Eds., The Carbonic Anhydrases, Birkhauser Verlag New Horizons, Basel, 2000, pp. 343-361.
[13] A. Nogradi, “The Role of Carbonic Anhydrases in Tumors,” American Journal of Pathology, Vol. 153, No. 1, 1998, pp. 1-4.
[14] W. Merz, “The Essential Trace Elements,” Science, Vol. 213, No. 4514, 1981, pp. 1332-1338.
[15] E. Mandishona, A. P. MacPhail, V. R. Gordeuk, M. A. Kedda, A. C. Paterson, T. A. Rouault and M. C. Kew, “Dietary Iron Overload as a Risk Factor for Hepatocellular Carcinoma in Black Africans,” Hepatology, Vol. 27, No. 6, 1998, pp. 1563-1566.
[16] A. Barbouti, P. T. Doulias, B. Z. Zhu, B. Frei and D. Galaris, “Intracellular Iron, But Not Copper, Plays a Critical Role in Hydrogen Peroxide-Induced DNA Damage,” Free Radical Biology & Medicine, Vol. 31, No. 4, 2001, pp. 490-498.
[17] K. T. Suzuki, M. Rui, J. Ueda and T. Ozawa, “Production of Hydroxyl Radicals by Copper-Containing Metallothionein: Roles as Prooxidant,” Toxicology and Applied Pharmacology, Vol. 141, No. 1, 1996, pp. 231-237.
[18] B. Halliwell and J. M. Gutteridge, “Oxygen Toxicity, Oxygen Radicals, Transition Metals and Diseases,” Biochemical Journal, Vol. 219, No. 1, 1984, pp. 1-14.
[19] A. Goel, V. Dani and D. K. Dhawan, “Protective Effects of Zinc on Lipid Peroxidation, Antioxidant Enzymes Hepatic Histoarchitecture in Chlorpyrifos-Induced Toxicity,” Chemico-Biological Interactions, Vol. 156, No. 2-3, 2005, pp. 131-140.
[20] M. Waisberg, P. Joseph, B. Hale and D. Beyersmann, “Molecular and Cellular Mechanisms of Cadmium Carcinogenesis,” Toxicology, Vol. 192, No. 2-3, 2003, pp. 95-117.
[21] S. Gwini, E. Macfarlane, A. Del Monaco, D. Mclean, D. Pisaniello, G. P. Benke and M. Ross Sim, “Cancer Incidence, Mortality, and Blood Lead Levels among Workers Exposed to Inorganic Lead,” Annals of Epidemiology, Vol. 22, No. 4, 2012, pp. 270-276.
[22] T. H. Maren, “Carbonic Anhydrase, Chemistry, Physiology and Inhibition,” Physiological Reviews, Vol. 47, No. 4, 1967, pp. 595-781.
[23] H. Aebi, “Catalase in Vitro. Methods of Enzymatic Analysis,” Academic Press, New York and London, 1974, pp. 673-676.
[24] E. Cadenas, “Biochemistry of Oxygen Toxicity,” Annual Review of Biochemistry, Vol. 58, 1989, pp. 79-110.
[25] Y. Sun, “Free Radicals, Antioxidant Enzymes and Carcinogenesis,” Free Radical Biology & Medicine, Vol. 8, No. 6, 1990, pp. 583-599.
[26] M. José, J. M. Matés, J. M Segura, C. Pérez-Gómez, R. Rosado, L. Olalla, et al., “Antioxidant Enzymatic Activities in Human Blood Cells after an Allergic Reaction to Pollen Or House Dust Mite,” Blood Cells, Molecules and Diseases, Vol. 25, No. 2, 1999, pp. 103-109. bcmd.1999.0234
[27] G. Bellisola, M. Casaril, G. B. Gabrielli, M. Caraffi and R. Corrocher, “Catalase Activity in Human Hepatocellular Carcinoma (HCC),” Clinical Biochemistry, Vol. 20, No. 6, 1987, pp. 415-417.
[28] A. Casado, R. Torre, M. E. Lopez-Fernandez, D. Carrascosa, M. C. Casado and M. V. Ramirez, “Superoxide Dismutase and Catalase Blood Levels in Patients with Malignant Diseases,” Cancer Letters, Vol. 93, No. 2, 1995, pp. l87-192.
[29] C. C. Lin and M. C. Yin, “B Vitamins Deficiency and Decreased Anti-Oxidative State in Patients with Liver Cancer,” European Journal of Nutrition, Vol. 46, No. 5, 2007, pp. 293-299.
[30] G. Bonapacea, F. Iuliano, S. Molica, A. Peta and P. Strisciuglio, “Cytosolic Carbonic Anhydrase Activity in Chronic Myeloid Disorders with Different Clinical Phenotype,” Biochimica et Biophysica Acta, Vol. 1689, No. 3, 2004, pp. 179-181.
[31] O. Ozensoy, F. Kockar, O. Arslan, S. Isik, C. T. Supuran and M. Lyon, “An Evaluation of Cytosolic Erythrocyte Carbonic Anhydrase and Catalase in Carcinoma Patients: An Elevation of Carbonic Anhydrase Activity,” Clinical Biochemistry, Vol. 39, No. 8, 2006, pp. 804-809.
[32] N. Hasebe, “Oxidative Stress and Magnesium,” Clinical Calcium, Vol. 15, No. 2, 2005, pp. 194-202.
[33] Y. Manuel, B. Keenoy, G. Moorkens, J. Vertommen, M. Noe, J. Neve and I. De Leeuw, “Magnesium Status and Parameters of the Oxidant Balance in Patients with Chronic Fatigue: Effect of Suplementation with Magnesium,” Journal of the American College of Nutrition, Vol. 19, No. 3, 2000, pp. 374-382.
[34] Q. Pasha, S. A. Malik and M. H. Shah, “Statistical Analysis of Trace Metals in the Plasma of Cancer Patients versus Controls,” Journal of Hazardous Materials, Vol. 153, No. 3, 2008, pp. 1215-1221.
[35] R. Seth, S. Yang, S. Choi, M. Sabean and E. A. Roberts, “In Vitro Assessment of Copper-?nduced Toxicity in the Human Hepatoma Line, Hep G2,” Toxicol ?n Vitro, Vol. 18, No. 4, 2004, pp. 501-509.
[36] M. Ebara, H. Fukuda, R. Hatano, M. Yoshikawa, N. Sugiura, H. Saisho, F. Kondo and M. Yukawa, “Metal Contents in the Liver of Patients with Chronic Liver Disease Caused by Hepatitis C Virus. Reference to Hepatocellular Carcinoma,” Oncology, Vol. 65, No. 4, 2003, pp. 323-330.
[37] A. Roguljic, A. Roth, K. Kolaric and Z. Maricic, “Iron, Copper, and Zinc Liver Tissue Levels in Patients with Malignant Lymphomas,” Cancer, Vol. 46, No. 3, 1980, pp. 565-569.<565::AID-CNCR2820460324>3.0.CO;2-N
[38] R. M. Leach, “Role of Manganese in Mucopolysaccharide Metabolism,” Federation Proceedings, Vol. 30, No. 3, 1971, pp. 991-994.
[39] S. Johnson, “The Possible Crucial Role of Iron Accumulation Combined with Low Tryptophan, Zinc and Manganese in Carcinogenesis,” Medical hypotheses, Vol. 57, No. 5, 2001, pp. 539-543.
[40] J. F. Feng, L. Lu, P. Zeng, Y. H. Yang, J. Luo, Y. W. Yang and D. Wang, “Serum Total Oxidant/Antioxidant Status and Trace Element Levels in Breast Cancer Patients,” International Journal of Clinical Oncology, Vol. 17, No. 6, 2012, pp. 575-583.
[41] S. Takikawa, “Changes in Serum Zn, Cu, Se, and Mn Levels in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma,” Journal of Clinical Biochemistry Nutrition, Vol. 8, No. 2, 1990, pp. 153-164.
[42] B. Desoize, “Metals and Metal Compounds in Carcinogenesis,” In Vivo, Vol. 17, No. 6, 2003, pp. 529-539.
[43] D. D. Miller, “Minerals,” In: O. R. Fennema, Ed., Food Chemistry, Marcel Dekker, New York, 1996, pp. 617-649.
[44] T. Maeda, M. Shimada, N. Harimoto, E. Tsujita, S. Maehara, T. Rikimaru, S. Tanaka, K. Shirabe and Y. Maehara, “Role of Tissue Trace Elements in Liver Cancers and Non-Cancerous Liver Parenchyma,” Hepatogastroenterology, Vol. 52, No. 61, 2005, pp. 187-190.
[45] M. Valko, C. J. Rhodes, J. Moncola, M. Izakovic and M. Mazur, “Free Radicals, Metals and Antioxidants in Oxidative Stress-Induced Cancer,” Chemico-Biological Interactions, Vol. 160, No. 1, 2006, pp. 1-40.
[46] K. Y. Liaw, P. H. Lee, F. C. Wu, J. S. Tsai, S. Y. Lin-Shiau, “Zinc, Copper, and Superoxide Dismutase in Hepatocellular Carcinoma,” The American Journal of Gastroenterology, Vol. 92, No. 12, 1997, pp. 2260-2263.
[47] P. W. Keeling, W. Ruse, J. Bull, B. Hannigan and R. P. Thompson, “Direct Measurement of the Hepatointestinal Extraction of Zinc in Cirrhosis and Hepatitis,” Clinical Science, Vol. 61, No. 4, 1981, pp. 441-444.
[48] G. Kazantzis, “Role of Cobalt, Iron, Lead, Manganese, Mercury, Platinum, Selenium and Titanium in Carcinogenesis,” Environmental Health Perspectives, Vol. 40, 1981, pp. 143-161.
[49] H. Ozmen, F. A. Erulas, F. Karatas, A. Cukurovali and O. Yalcin, “Comparison of the Concentration of Trace Metals (Ni, Zn, Co, Cu and Se), Fe, Vitamins A, C and E, and Lipid Peroxidation in Patients with Prostate Cancer,” Clinical Chemistry Laboratory Medicine, Vol. 44, No. 2, 2006, pp. 175-179.
[50] International Agency for Research on Cancer Monographs, “Beryllium, Cadmium, Mercury and Exposures in the Glass Industry, Vol. 58,” Internat?onal Agency for Research on Cancer, Lyon, 1993, pp. 119-238.
[51] P. Joseph, “Mechanisms of Cadmium Carcinogenesis,” Toxicology and Applied Pharmacology, Vol. 238, No. 3, 2009, pp. 272-279.
[52] O. Lahelma, M. Nuurtamo, A. Paaso, L. Rasanen, E. Saari and P. Varo, “Mineral Element Composition of Finnish Food: N, K, Ca, Mg, P, S, Fe, Cu, Mn, Zn, Mo, Co, Ni, Cr, F, Se, Si, Rb, Al, B, Br, Hg, As, Cd, Pb and Ash,” Acta Agriculture Scandinavia, Vol. 22, 1980, p. 171.
[53] I. Bremner, “Mammalian Absorption, Transport and Excretion of Cadmium,” In: M. Webb, Ed., Chemistry, Biochemistry and Biology of Cadmium, Elsevier/North-Holland Biomedical Press, Amsterdam, 1979, pp. 175-193.
[54] B. G. Armstrong and G. Kazantzis, “Prostatic Cancer and Chronic Respiratory and Renal Disease in British Cadmium Workers: A Case-Control Study,” British Journal of Industrial Medicine, Vol. 42, No. 8, 1985, pp. 540-545.
[55] IARC, “Inorganic and Organic Lead Compounds,” IARC Monograph, Vol. 87, France, 2006, pp. 10-17.
[56] E. K. Silbergeld, “Facilitative Mechanisms of Lead as a Carcinogen,” Mutation Research, Vol. 533, No. 1-2, 2003, pp. 121-133.
[57] V. Englyst, N. G. Lundstroma, L. Gerhardsson, L. Rylander and G. Nordberg, “Lung Cancer Risks among Lead Smelter Workers also Exposed to Arsenic,” The Science of the Total Environment, Vol. 273, No. 1-3, 2001, pp. 77-82.
[58] E. B. Southard, A. Roff, T. Fortugno, J. P. Richie, M. Kaag, V. M. Chinchilli, J. Virtamo, D. Albanes, S. Weinstein and R. T. Wilson, “Lead, Calcium Uptake, and Related Genetic Variants in Association with Renal Cell Carcinoma Risk in a Cohort of Male Finnish Smokers,” Cancer Epidemiology Biomarkers & Prevention, Vol. 21, No. 1, 2012, pp. 191-201.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.